SCIENTEX

SCIENTX
End-of-day quote. End-of-day quote  - 06/18
4.22MYR 0.00%
Income Statement Evolution
Annual Income Statement Data
Fiscal Period: July 2020 2021
Net sales1 3 5194 024
EBITDA1 657692
Operating profit (EBIT)1 549594
Operating Margin 15,6%14,8%
Pre-Tax Profit (EBT)1 544574
Net income1 390428
Net margin 11,1%10,6%
EPS2 0,250,29
Dividend per Share2 0,080,08
Last update 09/18/202004/06/2021
1 MYR in Million
2 MYR
Estimates
Finances - Leverage
Fiscal Period: July 2020 2021
Net Debt --
Net Cash position --
Leverage (Debt / EBITDA) --
Free Cash Flow --
ROE (Net Profit / Equities) 16,9%15,2%
Shareholders' equity1 2 3112 814
ROA (Net Profit / Asset) 9,28%8,90%
Assets1 4 2054 814
Book Value Per Share2 1,662,00
Cash Flow per Share --
Capex1 79,4150
Capex / Sales 2,26%3,73%
Last update 09/18/202003/17/2021
1 MYR in Million
2 MYR
Estimates
Balance Sheet Analysis
Financial Ratios
Size 2021e 2022e
Capitalization 6 544 M MYR -
Valuation 2021e 2022e
P/E ratio (Price / EPS) 14,5x 13,3x
Capitalization / Revenue 1,63x 1,44x
Yield (DPS / Price) 1,93% 2,22%
Price to book (Price / BVPS) 2,11x 1,88x
Profitability 2021e 2022e
Operating Margin (EBIT / Sales) 14,8% 14,7%
Operating Leverage (Delta EBIT / Delta Sales) 0,57x 0,94x
Net Margin (Net Profit / Revenue) 10,6% 11,0%
ROA (Net Profit / Asset) 8,90% 9,10%
ROE (Net Profit / Equities) 15,2% 16,2%
Rate of Dividend 27,9% 29,6%
Balance Sheet Analysis 2021e 2022e
CAPEX / Sales   3,73% 3,30%
Cash Flow / Sales - -
Capital Intensity (Assets / Sales) 1,20x 1,20x
Financial Leverage (Net Debt / EBITDA) - -
Price Earning Ratio
EPS & Dividend